It was a pleasure to speak with Bob Geng (University of California, San Diego, CA, USA) to give us an overview of immunoglobulin replacement therapy, and subcutaneous human IgG 16.5% in patients with immunodeficiencies. The abstract entitled ‘Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies‘ (ABSTRACT NUMBER: 238) […]